Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.39 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.35 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197751 | 0.87 | TGFBR1 (0.40) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL2197856 | 0.84 | TGFBR1 (0.52) | TGFBR1PRKD3PRKD1PRKD2CYP3A4 | |
| SCHEMBL12426198 | 0.83 | TGFBR1 (0.40) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL2200330 | 0.82 | NUDT1 (0.56) | TGFBR1CYP3A4NUDT1ACVR1BACVRL1 | |
| SCHEMBL2200336 | 0.80 | TGFBR1 (0.46) | TGFBR1NUDT1ACVR1BACVRL1ACVR1 | |
| SCHEMBL12426234 | 0.79 | TGFBR1 (0.39) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL8345664 | 0.75 | TGFBR1 (0.48) | TGFBR1PRKD3PRKD1PRKD2TGFBR2 | |
| SCHEMBL14533161 | 0.73 | TGFBR1 (0.40) | TGFBR1 | |
| SCHEMBL2198168 | 0.73 | PRKD3 (0.34) | TGFBR1PRKD3PRKD1PRKD2 | |
| SCHEMBL2200247 | 0.71 | PRKD3 (0.33) | TGFBR1PRKD3PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-7977342-B2 | HCV inhibiting bi-cyclic pyrimidines | TIBOTEC-VIRCO VIROLOGY BVBA (BE) | 2011-07-12 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155716-A1 | HCV INHIBITING BI-CYCLIC PYRIMIDINES | UMPS, NUDT1, PNP | TGFBR1 3900/4885PRKD3 3048/4885PRKD1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.